SK3232000A3 - MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL - Google Patents
MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL Download PDFInfo
- Publication number
- SK3232000A3 SK3232000A3 SK323-2000A SK3232000A SK3232000A3 SK 3232000 A3 SK3232000 A3 SK 3232000A3 SK 3232000 A SK3232000 A SK 3232000A SK 3232000 A3 SK3232000 A3 SK 3232000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- human
- monoclonal antibody
- iap
- antibody
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims description 27
- 108010033276 Peptide Fragments Proteins 0.000 title claims description 5
- 102000007079 Peptide Fragments Human genes 0.000 title claims description 5
- 230000006907 apoptotic process Effects 0.000 claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 14
- 210000000601 blood cell Anatomy 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000000719 anti-leukaemic effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract description 38
- 239000000427 antigen Substances 0.000 abstract description 26
- 102000036639 antigens Human genes 0.000 abstract description 26
- 108091007433 antigens Proteins 0.000 abstract description 26
- 230000001939 inductive effect Effects 0.000 abstract description 19
- 208000025113 myeloid leukemia Diseases 0.000 abstract description 7
- 208000028018 Lymphocytic leukaemia Diseases 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 174
- 101000688216 Homo sapiens Intestinal-type alkaline phosphatase Proteins 0.000 description 33
- 101000616014 Homo sapiens Magnesium transporter protein 1 Proteins 0.000 description 33
- 239000012228 culture supernatant Substances 0.000 description 30
- 108010044426 integrins Proteins 0.000 description 30
- 102000006495 integrins Human genes 0.000 description 30
- 238000000034 method Methods 0.000 description 26
- 210000004940 nucleus Anatomy 0.000 description 24
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 23
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 21
- 102000053119 human ALPI Human genes 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000012634 fragment Substances 0.000 description 14
- 102000003839 Human Proteins Human genes 0.000 description 13
- 108090000144 Human Proteins Proteins 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 210000000066 myeloid cell Anatomy 0.000 description 10
- 210000002536 stromal cell Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000001235 sensitizing effect Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 208000003747 lymphoid leukemia Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000000063 antileukemic agent Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000270 Ficain Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 2
- 235000019836 ficin Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063827 Extramedullary haemopoiesis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100340613 Mus musculus Iap gene Proteins 0.000 description 1
- 101000688214 Mus musculus Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 101000868281 Mus musculus Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000616015 Mus musculus Magnesium transporter protein 1 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000031957 myeloid cell apoptotic process Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26485397 | 1997-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3232000A3 true SK3232000A3 (en) | 2000-09-12 |
Family
ID=17409137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK323-2000A SK3232000A3 (en) | 1997-09-11 | 2000-03-07 | MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20030157100A1 (de) |
| EP (1) | EP1035132B1 (de) |
| KR (2) | KR20010023866A (de) |
| CN (1) | CN1198845C (de) |
| AT (1) | ATE395362T1 (de) |
| AU (1) | AU740225B2 (de) |
| CA (1) | CA2303072A1 (de) |
| DE (1) | DE69839492D1 (de) |
| HU (1) | HUP0003513A3 (de) |
| NO (1) | NO20001238L (de) |
| PL (1) | PL339265A1 (de) |
| RU (1) | RU2212413C2 (de) |
| SK (1) | SK3232000A3 (de) |
| WO (1) | WO1999012973A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006748A1 (fr) * | 1993-09-03 | 1995-03-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps monoclonal permettant d'induire une apoptose |
| US7531643B2 (en) * | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| WO2000053634A1 (fr) * | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Fv monocatenaire induisant l'apoptose |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| TWI242043B (en) * | 2000-03-10 | 2005-10-21 | Chugai Pharmaceutical Co Ltd | Polypeptide inducing apoptosis |
| WO2001079494A1 (fr) * | 2000-04-17 | 2001-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agonistes |
| US20040058393A1 (en) * | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
| AU1091702A (en) * | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded tpo agonist antibody |
| CN1308447C (zh) * | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
| AU2002210918B2 (en) * | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| ATE391174T1 (de) | 2000-10-20 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Modifizierter tpo-agonisten antikörper |
| US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
| DE60324700D1 (de) | 2002-10-11 | 2008-12-24 | Chugai Pharmaceutical Co Ltd | Zelltod-induzierender wirkstoff |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| US20070003556A1 (en) * | 2003-03-31 | 2007-01-04 | Masayuki Tsuchiya | Modified antibodies against cd22 and utilization thereof |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| EP1693385A4 (de) * | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | Humanisierter anti-cd47-antikörper |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| CA2548929A1 (en) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
| TW200530266A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Method of reinforcing antibody activity |
| JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| EP1870458B1 (de) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2-STRUKTURISOMERE |
| WO2006123724A1 (ja) * | 2005-05-18 | 2006-11-23 | The University Of Tokushima | 抗hla抗体を利用した新規医薬品 |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| JPWO2008007755A1 (ja) * | 2006-07-13 | 2009-12-10 | 中外製薬株式会社 | 細胞死誘導剤 |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| WO2009091547A1 (en) | 2008-01-15 | 2009-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| PT3056514T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação de fagocitose mediada por cd47 |
| US8951527B2 (en) | 2008-08-07 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
| KR102338833B1 (ko) * | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| ES2786083T3 (es) | 2012-12-12 | 2020-10-08 | Arch Oncology Inc | Anticuerpos terapéuticos CD47 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| BR112018005322A2 (pt) | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| EP3484448A4 (de) | 2016-07-13 | 2020-04-01 | President and Fellows of Harvard College | Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon |
| EP3529276A4 (de) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | Therapeutische cd47-antikörper |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| CN110066336B (zh) * | 2019-05-12 | 2021-11-09 | 杭州科兴生物科技有限公司 | 抗cd47单克隆抗体、片段及其医药用途 |
| IL312302A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for creating cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2150262C (en) * | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1995006748A1 (fr) * | 1993-09-03 | 1995-03-09 | Chugai Seiyaku Kabushiki Kaisha | Anticorps monoclonal permettant d'induire une apoptose |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| WO1997032601A1 (fr) * | 1996-03-06 | 1997-09-12 | Chugai Seiyaku Kabushiki Kaisha | Procede de criblage de substances induisant l'apoptose |
| US7531643B2 (en) * | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
| US7696325B2 (en) * | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
-
1998
- 1998-09-11 HU HU0003513A patent/HUP0003513A3/hu unknown
- 1998-09-11 KR KR1020007002548A patent/KR20010023866A/ko not_active Application Discontinuation
- 1998-09-11 KR KR10-2004-7019086A patent/KR20040106585A/ko active IP Right Grant
- 1998-09-11 WO PCT/JP1998/004118 patent/WO1999012973A1/ja active IP Right Grant
- 1998-09-11 EP EP98941848A patent/EP1035132B1/de not_active Expired - Lifetime
- 1998-09-11 CA CA002303072A patent/CA2303072A1/en not_active Abandoned
- 1998-09-11 RU RU2000109293/13A patent/RU2212413C2/ru not_active IP Right Cessation
- 1998-09-11 AT AT98941848T patent/ATE395362T1/de not_active IP Right Cessation
- 1998-09-11 DE DE69839492T patent/DE69839492D1/de not_active Expired - Lifetime
- 1998-09-11 CN CNB988103435A patent/CN1198845C/zh not_active Expired - Fee Related
- 1998-09-11 AU AU90028/98A patent/AU740225B2/en not_active Ceased
- 1998-09-11 PL PL98339265A patent/PL339265A1/xx unknown
-
2000
- 2000-03-07 SK SK323-2000A patent/SK3232000A3/sk unknown
- 2000-03-09 NO NO20001238A patent/NO20001238L/no unknown
-
2003
- 2003-03-10 US US10/383,512 patent/US20030157100A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20001238D0 (no) | 2000-03-09 |
| AU9002898A (en) | 1999-03-29 |
| DE69839492D1 (de) | 2008-06-26 |
| CN1276798A (zh) | 2000-12-13 |
| RU2212413C2 (ru) | 2003-09-20 |
| NO20001238L (no) | 2000-05-11 |
| EP1035132A1 (de) | 2000-09-13 |
| WO1999012973A1 (fr) | 1999-03-18 |
| AU740225B2 (en) | 2001-11-01 |
| ATE395362T1 (de) | 2008-05-15 |
| EP1035132B1 (de) | 2008-05-14 |
| EP1035132A4 (de) | 2005-02-09 |
| HUP0003513A3 (en) | 2004-05-28 |
| CA2303072A1 (en) | 1999-03-18 |
| KR20010023866A (ko) | 2001-03-26 |
| PL339265A1 (en) | 2000-12-04 |
| US20030157100A1 (en) | 2003-08-21 |
| CN1198845C (zh) | 2005-04-27 |
| HUP0003513A2 (hu) | 2001-02-28 |
| KR20040106585A (ko) | 2004-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3232000A3 (en) | MONOCLONAL ANTIBODY, FRAGMENT, PEPTIDE OR LOW MOLECULAR COMPOUNDì (54) FROM MONOCLONAL ANTIBODY, HYBRIDOMA PRODUCING MONOCL | |
| US7531643B2 (en) | Monoclonal antibody inducing apoptosis | |
| KR100795745B1 (ko) | 인슐린-유사 성장 인자 ⅰ 수용체에 대한 항체 및 그의용도 | |
| KR100919915B1 (ko) | Ｎｋｇ２ｄ의 조절 | |
| Uno et al. | Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia | |
| RU2177805C2 (ru) | Средство, применяемое при лечении опухолей лимфатической ткани | |
| CN111978402B (zh) | 新型cldn18.2结合分子 | |
| JP3568398B2 (ja) | アポトーシスを誘起するモノクローナル抗体 | |
| JP2023546743A (ja) | 抗ｃｄ７３抗体及びその使用 | |
| CZ2000907A3 (cs) | Monoklonální protilátka indukující apoptózu | |
| Wallén‐Öhman et al. | A cell surface antigen (BAL) defined by a mouse monoclonal antibody inducing apoptosis in a human lymphocytic leukemia cell line |